Conversion Surgery in Pancreatic Cancer View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2021-07-20

AUTHORS

Akio Saiura

ABSTRACT

Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) is divided into metastatic PDAC (mPDAC) and locally advanced PDAC (LA-PDAC). Conversion surgery (CS) has been gaining more attention due to the advent of effective systemic chemotherapy and surgical innovation of pancreatectomy with vascular resection and reconstruction. A significant improvement in overall survival has been reported in retrospective and prospective cohort studies. However, there are no robust data which indicate the clear benefit of CS and no consensus of the indication and optimal timing of CS for initially unresectable pancreatic cancer. Several prospective clinical trials are ongoing to clarify the benefit of CS for UR-PDAC. More... »

PAGES

83-94

Book

TITLE

Management of Pancreatic Cancer and Cholangiocarcinoma

ISBN

978-981-16-2869-6
978-981-16-2870-2

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8

DOI

http://dx.doi.org/10.1007/978-981-16-2870-2_8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1139801657


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258269.2", 
          "name": [
            "Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saiura", 
        "givenName": "Akio", 
        "id": "sg:person.0612301703.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612301703.87"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2021-07-20", 
    "datePublishedReg": "2021-07-20", 
    "description": "Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) is divided into metastatic PDAC (mPDAC) and locally advanced PDAC (LA-PDAC). Conversion surgery (CS) has been gaining more attention due to the advent of effective systemic chemotherapy and surgical innovation of pancreatectomy with vascular resection and reconstruction. A significant improvement in overall survival has been reported in retrospective and prospective cohort studies. However, there are no robust data which indicate the clear benefit of CS and no consensus of the indication and optimal timing of CS for initially unresectable pancreatic cancer. Several prospective clinical trials are ongoing to clarify the benefit of CS for UR-PDAC.", 
    "editor": [
      {
        "familyName": "Isayama", 
        "givenName": "Hiroyuki", 
        "type": "Person"
      }, 
      {
        "familyName": "Nakai", 
        "givenName": "Yousuke", 
        "type": "Person"
      }, 
      {
        "familyName": "Sasaki", 
        "givenName": "Takashi", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-981-16-2870-2_8", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-981-16-2869-6", 
        "978-981-16-2870-2"
      ], 
      "name": "Management of Pancreatic Cancer and Cholangiocarcinoma", 
      "type": "Book"
    }, 
    "keywords": [
      "conversion surgery", 
      "metastatic PDAC", 
      "pancreatic cancer", 
      "unresectable pancreatic ductal adenocarcinoma", 
      "unresectable pancreatic cancer", 
      "prospective cohort study", 
      "prospective clinical trials", 
      "effective systemic chemotherapy", 
      "pancreatic ductal adenocarcinoma", 
      "advanced PDAC", 
      "UR-PDAC", 
      "systemic chemotherapy", 
      "vascular resection", 
      "overall survival", 
      "cohort study", 
      "ductal adenocarcinoma", 
      "clinical trials", 
      "optimal timing", 
      "surgical innovation", 
      "surgery", 
      "robust data", 
      "cancer", 
      "clear benefit", 
      "PDAC", 
      "significant improvement", 
      "pancreatectomy", 
      "resection", 
      "chemotherapy", 
      "adenocarcinoma", 
      "trials", 
      "survival", 
      "benefits", 
      "indications", 
      "consensus", 
      "study", 
      "timing", 
      "improvement", 
      "more attention", 
      "reconstruction", 
      "data", 
      "advent", 
      "attention", 
      "innovation"
    ], 
    "name": "Conversion Surgery in Pancreatic Cancer", 
    "pagination": "83-94", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1139801657"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-981-16-2870-2_8"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-981-16-2870-2_8", 
      "https://app.dimensions.ai/details/publication/pub.1139801657"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_4.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-981-16-2870-2_8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8'


 

This table displays all metadata directly associated to this object as RDF triples.

112 TRIPLES      22 PREDICATES      67 URIs      60 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-981-16-2870-2_8 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N38304079aa4b4aeb8989d1d2d0894c0f
4 schema:datePublished 2021-07-20
5 schema:datePublishedReg 2021-07-20
6 schema:description Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) is divided into metastatic PDAC (mPDAC) and locally advanced PDAC (LA-PDAC). Conversion surgery (CS) has been gaining more attention due to the advent of effective systemic chemotherapy and surgical innovation of pancreatectomy with vascular resection and reconstruction. A significant improvement in overall survival has been reported in retrospective and prospective cohort studies. However, there are no robust data which indicate the clear benefit of CS and no consensus of the indication and optimal timing of CS for initially unresectable pancreatic cancer. Several prospective clinical trials are ongoing to clarify the benefit of CS for UR-PDAC.
7 schema:editor Na916fafad42e4828a032825d56f5d99f
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N6797721d688e461da8e4ff66af8bdbc1
11 schema:keywords PDAC
12 UR-PDAC
13 adenocarcinoma
14 advanced PDAC
15 advent
16 attention
17 benefits
18 cancer
19 chemotherapy
20 clear benefit
21 clinical trials
22 cohort study
23 consensus
24 conversion surgery
25 data
26 ductal adenocarcinoma
27 effective systemic chemotherapy
28 improvement
29 indications
30 innovation
31 metastatic PDAC
32 more attention
33 optimal timing
34 overall survival
35 pancreatectomy
36 pancreatic cancer
37 pancreatic ductal adenocarcinoma
38 prospective clinical trials
39 prospective cohort study
40 reconstruction
41 resection
42 robust data
43 significant improvement
44 study
45 surgery
46 surgical innovation
47 survival
48 systemic chemotherapy
49 timing
50 trials
51 unresectable pancreatic cancer
52 unresectable pancreatic ductal adenocarcinoma
53 vascular resection
54 schema:name Conversion Surgery in Pancreatic Cancer
55 schema:pagination 83-94
56 schema:productId N2bef08b19f7e4beaad6d6a172566f117
57 N6532bbd58b33474eb084d445e059c095
58 schema:publisher N71f00cfad9fa466ca75ec94265d9999c
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139801657
60 https://doi.org/10.1007/978-981-16-2870-2_8
61 schema:sdDatePublished 2022-10-01T06:58
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher Ncb140cd45a8c42d9b8bbe073878e7a03
64 schema:url https://doi.org/10.1007/978-981-16-2870-2_8
65 sgo:license sg:explorer/license/
66 sgo:sdDataset chapters
67 rdf:type schema:Chapter
68 N19cf5cebe6de467890c1f079f855e4d4 schema:familyName Sasaki
69 schema:givenName Takashi
70 rdf:type schema:Person
71 N2bef08b19f7e4beaad6d6a172566f117 schema:name dimensions_id
72 schema:value pub.1139801657
73 rdf:type schema:PropertyValue
74 N38304079aa4b4aeb8989d1d2d0894c0f rdf:first sg:person.0612301703.87
75 rdf:rest rdf:nil
76 N47dbd9155fd94051a1414d094ce43a51 schema:familyName Nakai
77 schema:givenName Yousuke
78 rdf:type schema:Person
79 N632d24d00410415d90eb3c8310a6a6fe rdf:first N19cf5cebe6de467890c1f079f855e4d4
80 rdf:rest rdf:nil
81 N6532bbd58b33474eb084d445e059c095 schema:name doi
82 schema:value 10.1007/978-981-16-2870-2_8
83 rdf:type schema:PropertyValue
84 N6797721d688e461da8e4ff66af8bdbc1 schema:isbn 978-981-16-2869-6
85 978-981-16-2870-2
86 schema:name Management of Pancreatic Cancer and Cholangiocarcinoma
87 rdf:type schema:Book
88 N71f00cfad9fa466ca75ec94265d9999c schema:name Springer Nature
89 rdf:type schema:Organisation
90 N882ddb66cd66412681af979824e56e91 rdf:first N47dbd9155fd94051a1414d094ce43a51
91 rdf:rest N632d24d00410415d90eb3c8310a6a6fe
92 Na916fafad42e4828a032825d56f5d99f rdf:first Nd7e2ba2150f145cda600ca9a89fe2b3a
93 rdf:rest N882ddb66cd66412681af979824e56e91
94 Ncb140cd45a8c42d9b8bbe073878e7a03 schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 Nd7e2ba2150f145cda600ca9a89fe2b3a schema:familyName Isayama
97 schema:givenName Hiroyuki
98 rdf:type schema:Person
99 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
100 schema:name Medical and Health Sciences
101 rdf:type schema:DefinedTerm
102 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
103 schema:name Oncology and Carcinogenesis
104 rdf:type schema:DefinedTerm
105 sg:person.0612301703.87 schema:affiliation grid-institutes:grid.258269.2
106 schema:familyName Saiura
107 schema:givenName Akio
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612301703.87
109 rdf:type schema:Person
110 grid-institutes:grid.258269.2 schema:alternateName Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan
111 schema:name Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan
112 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...